#United States #New York #The Gross Law Firm #Capricor Therapeutics #CAPR

Important Notice for Capricor Therapeutics Shareholders

The Gross Law Firm has made an urgent call to investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding a potential class action aimed at protecting their rights. Shareholders who acquired shares of Capricor during the class period from October 9, 2024, to July 10, 2025, are highly encouraged to reach out to the firm to discuss their options for recovery.

Background of the Case

The allegations put forth in the filed complaint indicate that Capricor Therapeutics misled investors by providing overly optimistic information regarding its primary cell therapy candidate, deramiocel, intended for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Specifically, the firm's assertions were aimed at reassuring investors about its ability to gain approval for a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA).

While the statements seemed positive, they were accompanied by false and misleading information, including critical data that showed a lack of substantial evidence from the safety and efficacy trials linked to deramiocel. Details emerging from the Phase 2 HOPE-2 clinical trial suggested negatives that were not disclosed to investors at the time.

The Critical Event

On July 11, 2025, Capricor disclosed that it had received a Complete Response Letter (CRL) from the FDA, effectively denying the BLA submission. The CRL indicated that Capricor failed to meet essential criteria concerning the effectiveness of deramiocel and noted the requirement for additional clinical data. This pivotal announcement led to a noticeable decline in Capricor's stock price, falling from $11.40 per share on July 10 to just $7.64 the following day, significantly impacting investors' portfolios.

Call to Action for Shareholders

Shareholders who purchased shares during the specified timeframe must act swiftly, as the deadline to register for participation in the class action is September 15, 2025. The registration process is straightforward, and there is no financial obligation involved.

Once you register, you will be integrated into a portfolio monitoring software that will keep you updated on the status of the case until its resolution. This proactive step allows shareholders to safeguard their rights and potentially reclaim losses incurred due to the alleged misconduct.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a reputable entity in handling class action lawsuits, dedicated to defending the rights of investors who have faced losses due to deception and malpractice in corporate governance. Their mission focuses on upholding ethical standards in business practices and ensuring justice for investors misled by false or omitted information.

If you are one of the shareholders affected by this situation, do not hesitate to reach out to The Gross Law Firm for guidance and assistance. They are committed to providing comprehensive support throughout this legal process.

Contact Information

• - The Gross Law Firm

15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Seize this opportunity to protect your investment. Time is of the essence, and acting promptly could potentially lead to financial recovery for shareholders of Capricor Therapeutics.